BRISTOL MYERS SQUIBB CO Logo

BRISTOL MYERS SQUIBB CO

Develops innovative medicines for oncology, immunology, and cardiovascular diseases.

BMY | US

Overview

Corporate Details

ISIN(s):
US1101222073 (+1 more)
LEI:
Country:
United States of America
Address:
ROUTE 206 AND PROVINCE LINE ROAD, 8543 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines to help patients prevail over serious diseases. The company's primary focus is on therapeutic areas with significant unmet medical needs, including oncology, hematology, immunology, and cardiovascular disease. Its operations encompass the full lifecycle of drug development, from scientific research and clinical trials to manufacturing, marketing, and distribution of its products worldwide. The company is committed to transforming patients' lives through scientific innovation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 17:06
Regulatory News Service
FORM 8-K
English 1.6 MB
2025-11-07 17:11
Prospectus
424B5
English 673.2 KB
2025-11-05 22:50
Regulatory News Service
FWP
English 17.4 KB
2025-11-04 23:19
Director's Dealing
FORM 4
English 7.4 KB
2025-11-04 23:18
Director's Dealing
FORM 4
English 8.2 KB
2025-11-04 23:15
Director's Dealing
FORM 4
English 7.5 KB
2025-11-04 23:13
Director's Dealing
FORM 4
English 7.7 KB
2025-11-03 12:09
Regulatory News Service
CURRENT REPORT
English 738.5 KB
2025-11-03 12:02
Prospectus
424B2
English 609.2 KB
2025-10-31 14:48
Major Shareholding Notification
English 8.6 KB
2025-10-30 17:04
Quarterly Report
10-Q
English 2.3 MB
2025-10-30 12:09
Regulatory News Service
8-K
English 2.9 MB
2025-10-06 23:22
Director's Dealing
FORM 4
English 7.4 KB
2025-10-03 00:20
Director's Dealing
FORM 4
English 7.4 KB
2025-10-03 00:18
Director's Dealing
FORM 4
English 7.3 KB

Automate Your Workflow. Get a real-time feed of all BRISTOL MYERS SQUIBB CO filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BRISTOL MYERS SQUIBB CO

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BRISTOL MYERS SQUIBB CO via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America OPT

Talk to a Data Expert

Have a question? We'll get back to you promptly.